Phase II Study Shows No Improvement in PFS with Addition of Pertuzumab

A study of 149 women with platinum sensitive ovarian cancer, half treated with carboplatin and paclitaxel or gemcitabine, half with that treatment plus pertuzumab, showed that the addition of pertuzumab to chemotherapy did not significantly increase progression free survival (PFS). However, the drug was described as “well-tolerated” and did not appear to increase the risk of cardiac events.

Read the abstract here